Parkville, Victoria, Australia
Innovation and results-driven Infection & Immunology Researcher with extensive experience across academia and industry, leading multidisciplinary teams in the discovery and preclinical development of novel therapeutics and vaccine candidates targeting antibiotic-resistant bacterial pathogens ("superbugs"). Proven expertise in antimicrobial resistance (AMR), mucosal immunology, host-pathogen interactions, and microbiology, with a strong focus on preclinical models (in vitro & in vivo) for infectious diseases such as non-tuberculous mycobacteria (NTM), urinary tract infections, Helicobacter pylori-associated gastric cancer, cystic fibrosis-related infections, and COVID-19. Skilled in a broad range of immunological and microbiological techniques, and passionate about translating cutting-edge research into real-world therapeutic solutions. Demonstrated success in securing funding, publishing high-impact peer-reviewed research, and driving collaborations across academic, clinical, and biotech sectors. PhD in Molecular Microbiology (The University of Queensland), with a strong track record of science communication, stakeholder engagement, and strategic project leadership in the global fight against antimicrobial resistance.
Leading preclinical efficacy trials and mechanism of action studies of novel clinical-stage (Phase I/II) synthetic antimicrobial in collaboration with our Industry partner.
Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences
Commercialisation Training for Medical and MedTech Researchers Delivered in collaboration with AAMRI VIC, MTPConnect, and Swinburne University of Technology, the 2025 training program equipped early to mid-career researchers to realise the commercialisation potential of their world-class research into real-world impact. This training pilot program was generously supported by the Victorian Government through the Skills Solutions Partnerships Program in the Department of Jobs, Skills Industry and Regions. The training program’s Final Pitch Night, held on 4 June 2025, marked the graduation of the inaugural participants of the Commercialisation Training for Medical and MedTech Researchers. The event showcased the top ten pitch finalists (including my project on anti-Helicobacter therapeutics), selected by investors from a total of 42 participants across Cohorts 1 and 2.
The Biotech Innovators Program is an initiative aimed at Victorian-based scientists, researchers, clinicians, SMEs, and tech transfer professionals who wished to enhance their research translation skills. Participants gained foundational knowledge of therapeutic development theory and explored various pathways and frameworks under the mentorship of the Brandon Capital investment team. The program featured internationally recognized guest speakers who shared their personal experiences, helping participants understand the real-world application of these pathways. Interactive workshops were a key component, allowing participants to apply learned concepts and develop a business plan for their research idea. By joining this program, participants connected with a cohort of like-minded professionals, expanding their networks and engaging in a transformative journey that addressed common challenges and opportunities within the biotech field.